Trials / Completed
CompletedNCT02379741
ADC-1013 First-in-Human Study
A First-in-human, Multicenter, Open-label, Multiple Ascending Dose Phase I Study in Patients With Advanced Solid Tumors to Determine the Safety, Pharmacokinetics and Pharmacodynamics of Intratumorally or Intravenously Administered ADC-1013
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Alligator Bioscience AB · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether ADC-1013 (an agonistic human monoclonal IgG1 anti-CD40 antibody) is safe and tolerable when administered intratumorally (as repeated injections directly into the tumor tissue) or intravenously (as repeated doses directly into a vein) in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ADC-1013 | Agonistic human monoclonal IgG1 anti-CD40 antibody |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2017-03-08
- Completion
- 2017-03-08
- First posted
- 2015-03-05
- Last updated
- 2017-03-27
Locations
5 sites across 3 countries: Denmark, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT02379741. Inclusion in this directory is not an endorsement.